Literature DB >> 26190462

Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.

Mandi M Murph1, Guowei W Jiang2, Molly K Altman3, Wei Jia3, Duy T Nguyen3, Jada M Fambrough3, William J Hardman4, Ha T Nguyen3, Sterling K Tran3, Ali A Alshamrani3, Damian Madan5, Jianxing Zhang2, Glenn D Prestwich6.   

Abstract

Autotaxin (ATX) is an enzyme discovered in the conditioned medium of cultured melanoma cells and identified as a protein that strongly stimulates motility. This unique ectonucleotide pyrophosphatase and phosphodiesterase facilitates the removal of a choline headgroup from lysophosphatidylcholine (LPC) to yield lysophosphatidic acid (LPA), which is a potent lipid stimulator of tumorigenesis. Thus, ATX has received renewed attention because it has a prominent role in malignant progression with significant translational potential. Specifically, we sought to develop active site-targeted irreversible inhibitors as anti-cancer agents. Herein we describe the synthesis and biological activity of an LPC-mimetic electrophilic affinity label that targets the active site of ATX, which has a critical threonine residue that acts as a nucleophile in the lysophospholipase D reaction to liberate choline. We synthesized a set of quaternary ammonium derivative-containing vinyl sulfone analogs of LPC that function as irreversible inhibitors of ATX and inactivate the enzyme. The analogs were tested in cell viability assays using multiple cancer cell lines. The IC50 values ranged from 6.74 to 0.39 μM, consistent with a Ki of 3.50 μM for inhibition of ATX by the C16H33 vinyl sulfone analog CVS-16 (10b). A phenyl vinyl sulfone control compound, PVS-16, lacking the choline-like quaternary ammonium mimicking head group moiety, had little effect on cell viability and did not inhibit ATX. Most importantly, CVS-16 (10b) significantly inhibited melanoma progression in an in vivo tumor model by preventing angiogenesis. Taken together, this suggests that CVS-16 (10b) is a potent and irreversible ATX inhibitor with significant biological activity both in vitro and in vivo.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Anticancer therapy; Autotaxin; Lysophosphatidylcholine; Melanoma; Vinyl sulfone

Mesh:

Substances:

Year:  2015        PMID: 26190462      PMCID: PMC4554797          DOI: 10.1016/j.bmc.2015.06.054

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  55 in total

1.  What is a good model for melanoma?

Authors:  Meenhard Herlyn; Mizuho Fukunaga-Kalabis
Journal:  J Invest Dermatol       Date:  2010-04       Impact factor: 8.551

2.  Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin.

Authors:  Gangadhar G Durgam; Tamas Virag; Michelle D Walker; Ryoko Tsukahara; Satoshi Yasuda; Karoly Liliom; Laurens A van Meeteren; Wouter H Moolenaar; Nicole Wilke; Wolfgang Siess; Gabor Tigyi; Duane D Miller
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

Review 3.  ATX-LPA receptor axis in inflammation and cancer.

Authors:  Shuying Liu; Mandi Murph; Nattapon Panupinthu; Gordon B Mills
Journal:  Cell Cycle       Date:  2009-11-27       Impact factor: 4.534

4.  Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs.

Authors:  E Jeffrey North; Daniel A Osborne; Peter K Bridson; Daniel L Baker; Abby L Parrill
Journal:  Bioorg Med Chem       Date:  2009-03-21       Impact factor: 3.641

5.  Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.

Authors:  Zendra Lee; Ramona F Swaby; Yuewei Liang; Shuangxing Yu; Shuying Liu; Karen H Lu; Robert C Bast; Gordon B Mills; Xianjun Fang
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

6.  Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.

Authors:  Shuying Liu; Makiko Umezu-Goto; Mandi Murph; Yiling Lu; Wenbin Liu; Fan Zhang; Shuangxing Yu; L Clifton Stephens; Xiaojiang Cui; George Murrow; Kevin Coombes; William Muller; Mien-Chie Hung; Charles M Perou; Adrian V Lee; Xianjun Fang; Gordon B Mills
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

7.  Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.

Authors:  Honglu Zhang; Xiaoyu Xu; Joanna Gajewiak; Ryoko Tsukahara; Yuko Fujiwara; Jianxiong Liu; James I Fells; Donna Perygin; Abby L Parrill; Gabor Tigyi; Glenn D Prestwich
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

8.  ATX expression and LPA signalling are vital for the development of the nervous system.

Authors:  Stella Fotopoulou; Nikos Oikonomou; Elena Grigorieva; Ioanna Nikitopoulou; Triantafillos Paparountas; Artemis Thanassopoulou; Zhenwen Zhao; Yan Xu; Dimitris L Kontoyiannis; Eumorphia Remboutsika; Vassilis Aidinis
Journal:  Dev Biol       Date:  2010-01-15       Impact factor: 3.582

Review 9.  Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors.

Authors:  Xiaoyu Xu; Guanghui Yang; Honglu Zhang; Glenn D Prestwich
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-08-12       Impact factor: 3.072

10.  Optimization of a pipemidic acid autotaxin inhibitor.

Authors:  Adrienne B Hoeglund; Heidi E Bostic; Angela L Howard; Irene W Wanjala; Michael D Best; Daniel L Baker; Abby L Parrill
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

View more
  3 in total

1.  Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p.

Authors:  Sudeepti S Kuppa; Wei Jia; Shuying Liu; Ha Nguyen; Susan S Smyth; Gordon B Mills; Kevin K Dobbin; William J Hardman; Mandi M Murph
Journal:  Cancer Lett       Date:  2018-05-31       Impact factor: 8.679

2.  Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo.

Authors:  Christian A Kuttruff; Marco Ferrara; Tom Bretschneider; Stefan Hoerer; Sandra Handschuh; Bernd Nosse; Helmut Romig; Paul Nicklin; Gerald J Roth
Journal:  ACS Med Chem Lett       Date:  2017-11-08       Impact factor: 4.345

Review 3.  MicroRNA Regulation of the Autotaxin-Lysophosphatidic Acid Signaling Axis.

Authors:  Mandi M Murph
Journal:  Cancers (Basel)       Date:  2019-09-14       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.